AstraZeneca, Swedish Orphan Biovitrum AB (publ) (Sobi) and Sanofi have updated and simplified their contractual arrangements relating to the development and commercialisation of nirsevimab in the US. Given the upcoming launch of nirsevimab in the US and other markets, simplification of the prior arrangements clarifies the roles and responsibilities of relevant parties.
Findings presented at ENDO 2023 also confirm analytical validity of company's TERT promoter gene mutation testing for thyroid nodule patients
Veracyte, Inc. (NASDAQ:VCYT) announced that new data presented at ENDO